 |
Italian Scientists and Scholars of North America Foundation
|
|
Home > USA > Meet Italy at Bio 2007
NANOVECTOR SRL
Via Livorno 60 - 10144 Torino,ITALY
Telephone: 390112258921
Web site: www.nanovector.it
E-mail: paolo.gasco@nanovector.it
Contact: Paolo gasco (CEO)
At a Glance
Status: SME
Date of foundation: 2003
Employees: 4
Turnover: 240.000.Euro
Export% : 60%
Main Activity
NANOVECTOR is R&D consultancy based company, having specific skill and expertise in Solid Lipid Nanoparticles (SLNs) and Micro-emulsions, which have been studied as colloidal carriers for drug delivery. SLNs are obtained by warm microemulsions by proprietary method. The company is equipped with all equipment required to develop on bench scale the SLN and micro-emulsion preparations, to characterise them for size, poly-dispersity index, zeta potential, and for chemical analyses. NV has in its facilities a working clean-room (class A) for study of pharmaceutical process development in sterile condition: cGMP scale-up for production of SLNs is in progress. Solid Lipid Nanoparticles (SLNs) are obtained from warm oil in water (O/W) and water in oil in water (W/O/W) micro-emulsions, as by proprietary methods. SLNs can be loaded with hydrophobic and hydrophilic drugs. NANOVECTOR has also a great expertise in the field of micro-emulsions prepared at room temperature. Company's core business is to apply and commercialise SLN technology for drug delivery in Pharmaceuticals.
Microemulsions and SLNs are constituted of bio-molecules, such as fatty acids, triglycerides, phospholipids. SLNs are solidified droplets of warm microemulsion and so they have a spherical shape with average diameter usually between 100 and 200 nanometers, depending on molecule to be loaded in: size distribution is very narrow. SLNs can also be prepared Stealth for IV adm., in order to avoid RES recognition, to prolong MRT and to better reach brain district.
Main results obtained by invitro and invivo tests on SLNs are following:
- SLNs can be administered, after testing in animal model, by intravenous, oral/duodenal, ocular and transdermal route.
- SLN are a slow release system: increasing of Area Under the Curve (AUC) and the Mean Residence Time (MRT) have been shown, comparing with reference market product.
- After administration by duodenal/oral route, SLNs are targeted to Lymph: relevant pharmacokinetic studies showed higher peak plasma concentrations (increasing AUC and MRT) after oral/duodenal SLNs administration vs the commercial forms of the same drug (solution) administered by Intravenous route.
- SLNs proved after in vivo tests to be able to overcome Physiological barriers (blood brain barrier (IV adm), blood retina barrier (topical, eye drops, adm))
- SLN are up-taken within few minutes in neoplastic and not neoplastic cell lines: invitro activity of anticancer drugs have been shown to be greatly enhanced when formulated in SLN comparing with market drug formulation
Company Strengths
HIGH QUALITY PRODUCTS: Solid Lipid Nanoparticles and Microemulsions for smart Drug Delivery of hydrophobic and hydrophilic drugs. Specific proprietary technical platform. Specific experitise and know-how. Possible way to extend product life for molecules going out of patent.
LICENSES/TRADE MARKS/QUALITY CERTIFICATIONS/PATENTS: 10 patents, uses and process, granted and pending.
INNOVATIVE PROCESSES/SERVICES/PRODUCTS: Transdermal administration of SLN, Eye topical administration of SLN for therapeutical application in diseases of posterior eye, SLN as carriers for nucleic acid, Antiinflammatory activity of SLNs having a lipid matrix working as prodrug of butyrate.
R&D CAPACITY: Colloidal Lipid Carriers, Microemulsions and Solid Lipid Nanoparticles. Feasibility studies for loading of customer's candidate in lipid carriers following proprietary methods.
NETWORKING: University of Torino, Politecnico of Torino, University of Milano, University of Piemonte Orientale, Bonsai Project Partners Network (project funded by EC , FP6)
EXPERTISE: Microemulsions at room temperature, Solid Lipid Nanoparticles obtained from warm microemulsions, loading in SLN of Hydrophobic drugs (best candidates) and Hydrophilic drugs (2 alternative methods).
Customer References
Big Pharma
- biotech companies
- government agencies
- merchant banks
- academia
Sector
BIOTECHNOLOGY
MEDICAL BIOTECHNOLOGY
-Genomics
-Immunology
-Nanotechnology
-Diagnostics
-Bioinformatics
-Drug delivery & Medical devices
Type of Cooperation
GENERAL CO-OPERATION
-NEW PROJECTS DEVELOPMENT
-IDENTIFICATION OF NEW CUSTOMERS
-TECHNOLOGY TRANSFER OR PRODUCTION LICENSE
-DEVELOPMENT OF NEW PRODUCTS
FINANCIAL COOPERATION
-FINANCIAL PARTICIPATION
|
|
